Advanced Search

 

Study ID Status Title Patient Level Data
207266/084 Completed A Study to Assess the Effect of Repeat Dose NCE on the Steady-State Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects
207267 Not yet recruiting Assessment of Patients Treated with Albiglutide – Phase 2
207323 Active, not recruiting Burden of illness among patients with eosinophilic severe COPD
207348 Completed Meta-analysis of studies MEA112997 and MEA115588 of mepolizumab (SB240563) in severe asthma – additional subgroup analyses of exacerbations and investigation of relationship of FEV1 to exacerbations (eTrack Study Identifier 207348)
207387 Completed PGx7665: Exploratory Pharmacogenetic analysis of response to GSK2269557, a PI3 kinase delta inhibitor in patients from study 116678 with COPD
207389 Completed PGx7667 (207389) Exploratory Pharmacogenetic Investigation of Efficacy Response to mepolizumab in Eosinophilic Granulomatosis Polyangiitis (Churg-Strauss Syndrome) study 115921
207390 Not yet recruiting PGx7669: an exploratory pharmacogenetic efficacy investigation of steroid reduction in subjects with severe asthma treated with mepolizumab in 115575 and 115661
207449 Active, not recruiting Ulcerative Colitis and Crohn’s Disease: Resource Utilization and costs after initiation of biologics
207478 Completed Meta-Analysis Plan for GSK sponsored studies MEA117113 and MEA117106 of Mepolizumab (SB240563) in COPD – Analysis to assess effect of mepolizumab on rate of exacerbations requiring an emergency department visit or hospitalization and rate of severe exacerbations (eTrack Study Identifier 207478)
207499/039 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/040 Completed A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/041 Completed A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/042 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/076 Completed A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/091 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/110 Completed A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/111 Completed A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease
207499/121 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/125 Completed A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/156 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/157 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/168 Completed A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/180 Completed An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD Study Listed on ClinicalStudyDataRequest.com
207499/181 Completed A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207521 Completed PGx7673: Confirmatory Genetics Reporting and Analysis Plan: Efficacy pharmacogenetic analysis of SLE patients treated with Benlysta in study BEL113750 (eTrack Study ID 207521)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.